INTEGRA LIFESCIENCES HOLDINGS CORP
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $1.6B | $1.6B | $1.5B | $1.6B | $1.5B |
| Operating income | -$493.4M | $28.4M | $111.5M | $238.9M | $197.2M |
| Cost of revenue | $803.6M | $728.5M | $656.8M | $587.4M | $597.8M |
| Cash from operations | $50.4M | $129.4M | $140.0M | $264.5M | $312.4M |
| Capital expenditure | $81.4M | $104.4M | $66.9M | $42.3M | $48.0M |
| Free cash flow | -$31.1M | $25.0M | $73.1M | $222.1M | $264.4M |
| Share repurchases | $221,000 | $52.5M | $275.0M | $125.0M | $0 |
| Impairments | $511.4M | $0 | $0 | $0 | $2.8M |
| Total assets | $3.6B | $4.0B | $3.8B | $3.9B | $3.8B |
| Total liabilities | $2.6B | $2.5B | $2.2B | $2.1B | $2.1B |
Shares outstanding 77.8M · Free float 98.0%
Annual filing data through FY ended December 31, 2025; float as of July 11, 2026.